Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic DifferentiationMaría E. Figueroa, Ari Melnick, Kristy Wolniak et al.|Cancer Cell|2010Cited by 2.7k
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignanciesOmar Abdel‐Wahab, Ross L. Levine, Ann Mullally et al.|Blood|2009Cited by 718
A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients with Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLN <i>FGFR1</i>)Jason Gotlib, Srđan Verstovšek, Jean‐Jacques Kiladjian et al.|Blood|2021Cited by 51
FIGHT-203, an Ongoing Phase 2 Study of Pemigatinib in Patients With Myeloid/Lymphoid Neoplasms (MLNs) With Fibroblast Growth Factor Receptor 1 (<i>FGFR1</i>) Rearrangement (MLN<i>FGFR1</i>): A Focus on Centrally Reviewed Clinical and Cytogenetic Responses in Previously Treated PatientsSrđan Verstovšek, Jean‐Jacques Kiladjian, Jason Gotlib et al.|Blood|2022Cited by 14
Comprehensive response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: a proposal from the MLN International Working GroupWilliam Shomali, Jason Gotlib, Philomena Colucci et al.|Leukemia|2023Cited by 14